Study on bioenhancer in the treatment of tuberculosis with Rifampicin : An evidencebased update - A Randomized Controlled Tial

Rifampicin containing fixed-dosecombinations are the currently approved treatments against TB in India and worldover. Rifampicin is a potent drug to fight TB but it has some unpleasantside-effects that often forces the patients discontinue with the medicine. Risorineis a combination of currently used antitubercular drugs isoniazid andrifampicin mixed with a new ingredient piperine (an extract of black pepper). Thecombination tablet uses only 200 mg of rifampicin instead of 450 mg, butmaintains the same efficacy and therefore reduces the need for high doses. However there is lack of evidence for Risorine in south Indian population. The present study will be an evidence based report.